A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

Bao‐Zhong Zhang(Daqing Oilfield General Hospital), Jian‐Dong Huang(Sun Yat-sen University), Chris Chung‐Sing Chan(University of Hong Kong), Chris Chun-Yiu Chan(University of Hong Kong), Ye‐Fan Hu(University of Hong Kong), Smaranda Badea(University of Hong Kong), Kelvin Kai‐Wang To(Hong Kong Science and Technology Parks Corporation), Shuofeng Yuan(University of Hong Kong), Ivan Fan‐Ngai Hung(Chinese University of Hong Kong), Kaiming Tang(University of Hong Kong), Hin Chu(HKU-Pasteur Research Pole), Jasper Fuk‐Woo Chan(Hong Kong Baptist University), Xuansheng Lin(University of Hong Kong), Jian‐Piao Cai(University of Hong Kong), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Xiaolei Wang(Nanchang University), Li Liu(Hangzhou Hospital of Traditional Chinese Medicine), Zhiwei Chen(Fujian Medical University), Wen‐Jun Li(Chinese Academy of Sciences), Xuechen Li(University of Hong Kong), Ying Dou(University of Hong Kong), Jingchu Hu(BGI Group (China)), Kenn Ka‐Heng Chik(University of Hong Kong), Hua‐Rui Gong(University of Hong Kong), Vincent Kwok‐Man Poon(Queen Mary Hospital)
Emerging Microbes & Infections
January 1, 2021
Cited by 15


Related Papers